| HS Code | 117470 |
| Product Name | Chuanbai Likang Tablets Veterinary Grade API |
| Product Category | Veterinary Active Pharmaceutical Ingredient (API) |
| Grade | Veterinary Grade |
| Active Ingredient | Chuanbai Likang |
| Physical Form | Bulk API powder/material for further formulation |
| Intended Use | Manufacture of veterinary finished dosage forms |
| Compatible Dosage Forms | Tablets, Injections, Capsules, Powders, Granules, Premix, Solutions |
| Target Population | Veterinary animals as approved by label/formulation |
| Formulation Role | API component in all listed dosage forms |
| Quality Specification | Meets veterinary pharmacopoeia or approved enterprise standard |
| Packaging | Sealed containers with moisture-proof protection |
| Storage Conditions | Store in cool, dry, well-ventilated area; protect from light and moisture |
| Shelf Life | Typically 24 months from manufacture when stored under recommended conditions |
As an accredited Chuanbai Likang Tablets Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged in sealed double-layer polyethylene bags inside fiber drums, net weight 25 kg per drum, with tamper-evident labeling for safety. |
| Container Loading (20′ FCL) | A 20′ FCL container loading of Chuanbai Likang Tablets veterinary-grade API ensures safe, compliant, and efficient transport for various dosage forms. |
| Shipping | Shipping for Chuanbai Likang Tablets Veterinary Grade API is handled under strict temperature-controlled, moisture-protected conditions. Products are sealed in food-grade, tamper-evident containers with inert gas blanketing. International air and sea freight options available with full customs documentation, including SDS, COA, and origin certificates, ensuring safe, compliant delivery worldwide. |
| Storage | Store in a cool, dry, well-ventilated area at controlled room temperature, tightly sealed in its original container. Protect from light, moisture, and humidity. Avoid contact with incompatible substances such as strong oxidizers or acids. Keep out of reach of children and animals. Always follow manufacturer-specific labeling for stability and expiry. |
| Shelf Life | Shelf life is typically 24 months from manufacture date when stored in original sealed containers under cool, dry conditions. |
Chuanbai Likang Tablets Veterinary Grade API is screened through a 500 µm stainless-steel test sieve conforming to ISO 3310-1:2016 before charging; oversized material is passed through a cone mill with a 0.8 mm screen at 1,500 rpm. Lot-to-lot bulk density variance above 0.20 g/mL triggers pre-compaction rather than direct compression. In high-shear wet granulation, purified water or a 5% w/w povidone K30 binder solution is sprayed at 15-25 g/min per kg dry blend; impeller speed is maintained at 250-350 rpm with chopper at 1,800-2,400 rpm. Granulation endpoint is determined by loss-on-drying 1.5-2.5% following Ph. Eur. 2.2.32, not by fixed granulation time. Over-wetting to LOD > 3.0% produces screen-blocking during wet milling and hard tablets with disintegration exceeding 15 min in water at 37 ± 2 °C per Ph. Eur. 2.9.1. Dried granules are milled through 1.0 mm and blended with crospovidone 4.0% w/w, microcrystalline cellulose, and magnesium stearate 0.5% w/w. Lubrication is limited to 3-5 min at 15 rpm; extended blending increases tablet hardness variability due to shear-induced hydrophobic coating. Compression is run on a rotary tablet press with 8 mm flat-faced bevel-edge tooling at a target hardness of 60-80 N and friability below 1.0% per Ph. Eur. 2.9.7. Tablet weight uniformity is monitored every 15 min using 20-tablet samples with acceptance value AV ≤ 15.0 per Ph. Eur. 2.9.40. For low-dose formulations where assay is below 25 mg per unit, direct compression after geometric dilution in a V-blender at 12 rpm for 20 min may be used, but content uniformity requires RSD ≤ 5.0% across 10 stratified samples.
| Control point | Target or limit | Reference method |
|---|---|---|
| Dry screen aperture | 500 µm | ISO 3310-1:2016 |
| Wet granulation loss on drying | 1.5-2.5% | Ph. Eur. 2.2.32 |
| Tablet crushing strength | 60-80 N | Ph. Eur. 2.9.8 |
| Friability | ≤ 1.0% | Ph. Eur. 2.9.7 |
| Disintegration | ≤ 15 min in water | Ph. Eur. 2.9.1 |
| Content uniformity | AV ≤ 15.0 / RSD ≤ 5.0% | Ph. Eur. 2.9.40 |
A second process conflict appears when the granulation is overdried below 1.0% LOD; the granules become brittle, generating fines above 40% during compression, which increases capping and weight variation. Overdried granules may also produce static charge in low-humidity rooms; processing at 40-50% RH is required. For delayed-release veterinary tablets, the API is layered onto sugar spheres in a fluid-bed coater; published data for this specific API in delayed-release matrix is limited, so a pH-gradient dissolution test in 0.1 N HCl for 2 h followed by pH 6.8 phosphate buffer is used. Aqueous film coating with HPMC 6 cP at 3% w/w weight gain is applied if the API is bitter; pan speed 8-12 rpm, inlet air 60-70 °C, and spray rate 10-15 g/min per kg tablets prevent core erosion. Tablet packing lines must be metal-detectable at 0.5 mm ferrous and 1.0 mm non-ferrous sensitivity; halal and kosher certificates must be maintained if target markets require.
Solution injections require an aqueous solubility screen at 20 °C and 37 °C in pH 3.0, 5.0, 6.5, and 7.4 buffers. If solubility remains above the target dose in a 10 mL dose volume, the API is dissolved in Water for Injection cooled to 25 °C, adjusted with hydrochloric acid or sodium hydroxide to within ±0.2 pH units, then made to volume. Nitrogen sparging at 0.2 bar for 20 min reduces oxidative degradation in APIs containing phenolic or thioether groups. Terminal sterilization is selected only if the solution withstands an F0 ≥ 8 min at 121 °C with assay loss below 2.0%; otherwise aseptic filtration through a 0.22 µm PVDF membrane with a prefilter of 0.45 µm is adopted. For injectable-grade processing, bioburden before sterilizing filtration must not exceed 10 CFU/100 mL per Ph. Eur. 5.1.1. Filling is performed under Grade A laminar airflow inside Grade B background per EU GMP Annex 1. Tubing adsorption and leachable exposure are controlled by limiting product contact time to ≤ 4 h at 25 °C. Final containers are 20 mL Type I glass vials with bromobutyl stoppers; headspace oxygen is displaced with nitrogen to ≤ 2.0% residual oxygen. Particulate matter is checked against Ph. Eur. 2.9.19 or USP 788 with light obscuration. If the API has limited aqueous solubility, co-solvent systems using propylene glycol 10-30% v/v or glycofurol 10-20% v/v are screened for precipitation upon dilution in isotonic saline; precipitation at 1:10 dilution indicates a need for surfactant addition such as polysorbate 80 at 0.1-0.5% w/v. Compatibility with rubber closures is tested by storage at 25 °C/60% RH and 40 °C/75% RH for 3 months; hardness change of the stopper and extractable profile per Ph. Eur. 3.2.9 are recorded. Published data for this specific veterinary API in injectable presentations is limited, so forced degradation at 0.1 N HCl, 0.1 N NaOH, and 3% H₂O₂ must precede process validation.
Terminal sterilization cannot be assumed. The selection matrix starts with forced degradation at 60 °C for 10 days and photostability per ICH Q1B. If the API contains an ester linkage, autoclaving in phosphate or acetate buffers causes hydrolysis at pH above 6.0. Therefore, the solution is maintained at pH 3.5-5.0 and cooled immediately after heat exposure using a reverse heat exchanger with ≥ 90% heat recovery. Glass delamination is a failure mode observed in Type I vials with high pH and high temperature; vials are screened by USP 1660 and sulfate glass composition. In-line filter integrity is tested before and after filtration by bacterial retention per ASTM F838-20; minimum bubble point for a 0.22 µm PVDF filter in water-wet condition is ≥ 2.0 bar. For viscous non-aqueous injections containing propylene glycol, filtration pressure must not exceed 1.5 bar to avoid particle shedding. The filled vials undergo leak testing by helium or dye penetration; rejected containers with ramp pressure decay above 0.5 mbar/s are removed. Published data for this specific Chuanbai Likang API in long-acting injectable suspension is limited; a sterile bead mill with 0.3 mm zirconia beads may be required if particle size above 10 µm is not acceptable for syringeability. Particle size distribution is then measured by laser diffraction per ISO 13320:2020 with D90 ≤ 10 µm and D50 ≤ 3 µm.
Filling hard gelatin or HPMC capsules places a 100% weight fill target on the dosator or tamping pin; therefore bulk density must be controlled between 0.45 g/mL and 0.75 g/mL after tapped density measurement per Ph. Eur. 2.9.34. Powder blend is prepared by geometric dilution in a 600 L bin blender at 10 rpm for 18 min. Materials with angle of repose above 40° are rejected for capsule filling unless silicified microcrystalline cellulose is added at 20-35% w/w and glidant silicon dioxide at 0.5-1.0% w/w. Capsule size selection is based on tapped bulk density: a 300 mg fill requires size 1 at 0.65 g/mL but size 0 at 0.50 g/mL. For low-dose capsules containing ≤ 10 mg API, slugging or roller compaction densification at 6-10 kN/cm reduces segregation and improves content uniformity to RSD ≤ 4.0% per Ph. Eur. 2.9.40. During automatic filling, tamping force is set between 50 N and 150 N for granular fills, while powders may require 200 N. Plug ejection force above 18 N causes telescoping or splitting, especially in HPMC capsules stored below 35% RH. Empty capsule moisture is maintained at 13-16% w/w for gelatin; filled capsules are packed with desiccant if the API is hygroscopic above 60% RH. Dissolution is tested by USP 711 Apparatus II at 50 rpm in 900 mL of pH 1.2 for gelatin or pH 4.5 for HPMC, with sampling at 15, 30, 45, and 60 min. Cross-linking of gelatin shells is mitigated by avoiding formaldehyde-contaminated packaging and by adding glycine 1.0% w/w to the fill where aldehyde traces are suspected.
Capsule fill weight control depends on densification stage. A direct powder fill is only used when Carr index is below 20 and Hausner ratio below 1.25 per Ph. Eur. 2.9.36. If the API is cohesive, roller compaction at 8 kN/cm with screen 1.0 mm is inserted before blending; the compacted granules are then filled with plug-forming excipients such as lactose monohydrate 45% w/w and pregelatinized starch 20% w/w. Weight variation is monitored every 30 min with 20 capsules; acceptance criteria for weight are ± 7.5% for 300 mg fill and ± 5.0% for 500 mg fill per Ph. Eur. 2.9.40. Empty shell brittleness below 10% RH causes punch-through defects; capsule filling rooms are maintained at 40-50% RH and 20-25 °C. For hygroscopic APIs, low-moisture HPMC shells and foil blister packaging with desiccant are required; the blister cavity must have a water vapor transmission rate below 0.3 mg/day per blister. Dissolution failures in gelatin capsules are investigated for pellicle formation, which is assayed by USP 711 with and without pepsin at pH 5.0.
Oral drench solutions require the API to remain in solution at 5 °C and 40 °C for 24 h without precipitation. A stock concentrate is normally prepared at 20% w/v in propylene glycol or glycerol formal, then diluted with purified water to 5-10% w/v before filling into 1 L high-density polyethylene containers. The pH is adjusted to 4.0-6.5 where chemical stability permits; below 4.0 palatability and container extractables increase, while above 6.5 microbial growth risk increases. Preservatives are selected from sodium benzoate 0.1% w/v, potassium sorbate 0.1-0.15% w/v, or benzyl alcohol 0.5-1.0% w/v, with antimicrobial effectiveness tested per Ph. Eur. 5.1.3. The concentration of benzyl alcohol must remain below 1.0% in oral liquids intended for cats due to clinical adverse effects; label must state species restriction. Homogeneity is verified by sampling top, middle, and bottom of a 500 L mixing vessel after 15 min at 150 rpm; assay values must fall within 95.0-105.0% of label claim with RSD ≤ 2.0%. For reconstitutable powders or granules, the dry blend is filled into foil-lined pouches under nitrogen with residual moisture below 2.0% per Ph. Eur. 2.2.32; reconstitution time in water at 20 °C must be ≤ 90 s with no visible undispersed particles after passing through a 0.5 mm sieve. The product is stored at 25 °C/60% RH and 40 °C/75% RH for 6 months to verify pH drift below 0.3 units and assay loss below 5.0%.
Organoleptic masking uses sodium saccharin 0.05% w/v and mint or apple flavor 0.2% v/v; bitter APIs may require inclusion complexation with betadex 1:5 molar ratio, which changes dissolution but not bioavailability unless a safety study is filed. Viscosity of the final oral solution is maintained below 5 mPa·s to ensure consistent pour out; higher viscosity leads to residual volume above 2 mL in 100 mL bottles. For multi-dose containers, dropper accuracy is checked at 0.5 mL, 1.0 mL, and 2.0 mL deliveries. Extractables from HDPE closures are screened using Ph. Eur. 3.2.2; if the API is lipophilic, polyethylene terephthalate bottles are preferred to reduce sorption to ≤ 2.0% over 12 months. A photostability study per ICH Q1B is required for oral solutions; amber PET bottles provide light transmission below 10% between 290 nm and 450 nm.
In feed premix manufacture, a 0.5% or 5.0% active premix is diluted into a carrier system; the first step is adsorption of the API onto precipitated silica or calcium carbonate at 1:1 to 1:3 ratio to reduce electrostatic adhesion. Carrier selection is based on particle-size distribution between 180 µm and 850 µm, bulk density 0.55-0.75 g/mL, and oil absorption below 25%. Reworked fines below 180 µm increase dusting and carryover; particles above 1.00 mm promote segregation during auger conveying. Mixing is carried out in a double-ribbon blender at 40 rpm for 10-15 min after a two-step geometric dilution. Homogeneity is tested by taking 10 g samples from 25 points following ANOVA; the coefficient of variation must be ≤ 5.0% and individual results within 90.0-110.0% of label claim per Ph. Eur. 2.9.40. Carryover is measured by washing the mixer, auger, and cyclone after the batch; residual API must be below 0.1% of the next batch size or cleaning validation limit. Medicated feed is then produced by mixing 1-10 kg premix per tonne of feed. Published data for the uniformity of this specific Chuanbai Likang API in mineral-based carriers is limited; a pilot batch with tracer studies using riboflavin or iron oxide is required to establish ribbon blender dead zones. Physical stability of the premix is monitored for 12 months at 25 °C/60% RH; segregation potential is assessed by discharging the blender into 25 kg bags and sampling each bag. Electrostatic charge is reduced by maintaining 40-60% RH in the processing suite.
| Carrier | Bulk density | Particle-size target | Critical limitation |
|---|---|---|---|
| Precipitated silica | 0.08-0.15 g/mL | 10-50 µm | Use only as adsorbent; high dusting and static |
| Calcium carbonate | 0.80-1.00 g/mL | 50-200 µm | Density mismatch with organic feed material |
| Wheat middlings | 0.35-0.45 g/mL | 200-850 µm | Moisture-sensitive above 14% moisture content |
| Corn cob meal | 0.25-0.35 g/mL | 425-1000 µm | Low bulk density; segregates in auger transfer |
In high-fat feed mills, the premix is added before pellet conditioning at 75-85 °C for 30-60 s; heat-labile APIs require post-pelleting spraying or lower temperature. Stability during pelleting is tested by spiking premix into mash feed and passing through a ring die with 3 mm holes; assay loss above 5.0% indicates the need for fat-coated granules or microencapsulation. Cross-contamination in shared mills is managed by sequencing the batch after flushing with 25 kg ground corn; flush material is assayed until API content falls below 0.5% of the minimum therapeutic level. If the premix is intended for multi-species feeds, species-specific withdrawal periods must be calculated from residue depletion data; this veterinary API must not be used in animals producing milk for human consumption unless residue data supports a milk withdrawal time. Published data for this specific API in lactating food-producing species is limited; therefore default withdrawal periods should be conservative and supported by Commission Regulation (EU) No 37/2010 residue studies.
For water-soluble powders, the dry blend is prepared with lactose monohydrate or dextrose 70-90% w/w and sodium bicarbonate/citric acid effervescent pair at 10-15% w/w to ensure rapid wetting. Granulation is performed with ethanol 95% in a fluid-bed granulator at inlet air 45-55 °C and product temperature 28-32 °C; residual ethanol is controlled per Ph. Eur. 2.4.24 to below 0.5%. Final granules are sized between 200 µm and 1.0 mm; dust below 100 µm must be below 10% to prevent segregation and operator exposure. Bulk density target is 0.50-0.65 g/mL; tapped density per Ph. Eur. 2.9.34 is used to set pouch fill weight. Each 100 g pouch must dissolve in 10 L of water at 15 °C within 3 min with stirring at 100 rpm. Dispersion is assessed by passing the solution through a 150 µm sieve; residue after drying must be ≤ 0.5% of pouch weight. In drinking-line systems, the stock solution is prepared at 1.0% w/v and proportioned at 1:100 through a dosing pump; the final drinking water concentration is calculated from body weight and water consumption data, not from feed intake. Lines are flushed after medication with 10 L of clean water; residual API in flushing water must be below 0.1 mg/L where environmental risk assessment requires. Biofilm formation is controlled by limiting solution hold time to 12 h and by cleaning with hydrogen peroxide 1.5% or citric acid 1.0% between treatment cycles. The product is packaged in polyethylene-aluminum-foil laminate pouches with oxygen transmission below 0.5 cm³/m²/24 h/atm; desiccant is added if moisture uptake exceeds 2.0% over 6 months at 30 °C/65% RH.
Granule dissolution can be retarded by hydrophobic API coatings from earlier milling. To prevent this, the API is pre-blended with lactose 200 M and passed through a 500 µm mill before wet granulation. In fluid-bed drying, outlet air humidity above 20% RH causes partial surface rehydration and granule agglomeration above 1.4 mm. Dried granules are transferred quickly into foil pouches to limit moisture regain to ≤ 0.5% in 2 h. For effervescent granules, tablet hardness is not relevant, but granule porosity must be high; bulk density above 0.70 g/mL reduces dissolution rate, while below 0.45 g/mL causes dusting. A disintegration test in 200 mL water at 20 °C is used; the granule mass should disintegrate and disperse within 2 min. Because drinking water pH varies from 6.0 to 8.5, the formulation is buffered with citrate 5.0% w/w to hold final solution pH below 7.0 where solubility is stable. In-line dosing pumps are calibrated monthly using a 10 L graduated vessel; deviation must be below 5.0% of nominal flow rate. The API concentration in drinking water is confirmed by collecting water at the last nipple in the line; assay must be within 90.0-110.0% of the target. If the product is marketed for poultry, coccidiostat or antimicrobial carryover into the next flock must be assessed per regional feed-safety rules.
Competitive Chuanbai Likang Tablets Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
The commercial designation Chuanbai Likang Tablets Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions identifies a veterinary-grade active pharmaceutical ingredient whose listed processing envelope spans oral solid, parenteral, and feed-incorporated dosage forms. The word Tablets in the descriptor belongs to the trade designation rather than to a finished-dosage restriction; the accompanying list signals that the material may be evaluated in direct compression, encapsulation, solution compounding, granulation, and carrier-based premix operations. No public pharmacopoeial monograph or discrete manufacturer model number was available for this exact label in the provided source. Batch release therefore must be controlled by the manufacturer’s internal model code, site master file, and the route-specific specifications agreed with the registration holder. Published data for this specific configuration is limited; the statements below separate label-level claims from the general public standards applicable to multi-route veterinary APIs.
In technical purchasing terms, the product differs from most single-route veterinary APIs by the breadth of the listed formulation routes. A dedicated oral-powder grade may be released solely on particle size, bulk density, and total aerobic count, while an injectable grade is normally released with a defined endotoxin budget and a bioburden profile. The Chuanbai Likang listing contains both domains, which means the specification set should be treated as a matrix rather than a single line-entry. If a batch certificate contains only oral-solid release data, that certificate does not automatically qualify the same lot for sterile injection or terminal sterilization. Users should request the route-specific data package for each intended use.
The rationale for a multi-route veterinary API is usually supply-chain consolidation. A manufacturer may serve animal-health markets in which the same active substance is incorporated into oral boluses, water-soluble powders, feed premixes, and injectable formulations. Instead of maintaining three or four separate API grades with different drying, milling, and packaging cycles, a single crystallized or granulated material is released against several appended specifications. The naming style does not itself establish that the untreated API is ready-to-use for every route; rather, it indicates that the manufacturer has not restricted the batch to a single dosage category and accepts route-dependent testing. This is operationally significant because a direct-compression tablet grade often requires a coarse, free-flowing particle distribution, while an injectable solution grade is commonly processed as a fine or freely soluble solid. The two requirements are not automatically reconciled by the same particle-size profile.
On production-scale tablet lines, materials with a Carr index above 30 and a median particle size below approximately 20 µm may generate flow blockages in hoppers and die-fill variation on rotary presses running beyond 40,000 tablets/h. The same fine fraction may be useful for solution vessels because high surface area accelerates dissolution. Thus the label’s seven-route listing exposes the central trade-off: one physical specification may benefit liquid compounding while penalizing tablet flow. A buyer should compare the batch certificate’s D10, D50, and D90 values against the equipment-specific requirements. Laser diffraction analysis according to ISO 13320 is the common particle-sizing platform; sieve analysis alone is insufficient for injectable-relevant fines.
For oral solids and non-parenteral liquids, compendial microbial enumeration such as Ph. Eur. 2.6.12 or USP <61> usually applies, with acceptance thresholds set by the product type rather than the API alone. A dry oral API may be released with a total aerobic microbial count below 103 CFU/g and a combined yeast and mould count below 102 CFU/g, but these are not universal values; they depend on the target species, route, and immune status. For injectable processing, the same material must support a bioburden level that yields a sterility assurance level of at least 10-6 after terminal sterilization or aseptic filtration. Sterility testing is performed according to Ph. Eur. 2.6.1 or USP <71>. Endotoxin acceptance is dose-linked: general pharmacopoeial calculations often express the limit as K divided by the maximum dose rate, with K values such as 5 EU/kg per hour for intravenous administration in some species; final limits are species-specific and dosage-specific. For subcutaneously or intramuscularly administered veterinary formulations, the K value and the maximum dose conversion may differ; the applicant must justify the numerical threshold in the registration dossier. A label statement of injectable compatibility cannot substitute for these route-specific calculations.
Water activity, residual moisture, and packaging also shift across the listed formats. A tablet-direct compression grade stored in low-density polyethylene bags may pick up moisture if ambient relative humidity exceeds 60%; subsequent compression can produce sticking and tablet weight variation. For powders and granules packed in sachets, a loss on drying limit below 5% or a water activity below 0.6 at 25 °C is a common stability target to reduce microbial proliferation, but the exact figure must come from the product dossier. For injectable solutions, the final moisture content of the dry API is less critical than the assay on anhydrous basis, residual solvents, and particulate matter after reconstitution or dilution. Therefore, the same product label may require three different storage and sampling plans.
A direct-compression grade is frequently milled to a D90 below 250 µm with a D50 between 75 µm and 150 µm; these ranges support die-fill consistency and content uniformity, provided the formulation includes a free-flowing filler. An injectable grade, by contrast, is not primarily characterized by D90 but by the time to complete dissolution in the chosen vehicle, the clarity of the resulting solution, and the particulate matter count after optional filtration. If the API has been over-milled to improve dissolution, the resulting powder may be cohesive and electrostatically active. A rotary tablet press operating at compression forces of 10–20 kN may then show unacceptable weight variability, and a capsule dosator may require vacuum adjustment. This is the central formulation conflict for any API listed across both solid oral and parenteral routes.
Granulation can reduce this conflict. Wet high-shear granulation in a granulator with an impeller tip speed of 5–10 m/s followed by fluid-bed drying at inlet-air temperatures of 50–70 °C is used to densify fine API and reduce dust. The resulting granules can be milled to a D90 of 1,000 µm or less for tablet compression or filled into sachets. Granulation changes dissolution profile, however, because the granule binder and compaction step reduce the available surface area. For injectable or solution applications, the granulated form may not dissolve quickly; a separate ungranulated micronized lot is often required. Thus the label listing should be understood as a family of possible uses rather than a single all-route optimized powder.
A typical single-route API may have one identification, assay, related substances, moisture, residue on ignition, particle size, and microbial count block. A multi-route API should additionally carry a route-specific microbial and endotoxin block when the intended destination includes injections. If the lot is intended for premix, assay homogeneity in the final feed is an essential release criterion after dilution. The European Pharmacopoeia general texts and VICH guidelines do not automatically impose a fixed homogeneity limit; typical premix quality programs use a relative standard deviation of 5% or lower across 10 sampled points, with the exact number defined by the manufacturer’s validated sampling plan. Equipment such as ribbon mixers, double-cone blenders, or paddle mixers operating at 20–50 rpm may require geometric dilution if the API is potent and the premix inclusion rate is low. These constraints are not relevant to a dedicated tablet-grade API purchase.
For solutions, the purity profile must include clarity and particulate-matter testing after reconstitution. Visible particulate inspections are performed using light obscuration methods such as Ph. Eur. 2.9.19 or USP <788>, with acceptance limits of 6,000 particles per container for particles ≥ 10 µm and 600 particles per container for particles ≥ 25 µm in large-volume parenterals. These limits are not automatically applicable to small-volume veterinary injections; the applicable monograph or registration file provides the actual acceptance criteria. A water-soluble powder for oral solution is less demanding on particulate matter but requires rapid and complete dissolution in potable water at drinking-water temperature, often below 20 °C in winter housing. Dissolution testing for oral powders, where applicable, may be executed in pH 6.8 phosphate buffer or in the intended drinking-water matrix, with sampling at 15 min, 30 min, and 45 min. These route-specific requirements create a broader analytical workload than a single-route grade.
The primary difference is documentation intensity. A dedicated oral tablet API may be released with a particle-size and moisture specification only; a dedicated injectable API requires endotoxin, bioburden, particulate, and possibly solvent-residue testing that is more restrictive. The Chuanbai Likang listing does not state that every batch is injected or terminally sterilized; it states that the grade may be assessed against injectable, oral, powder, and premix criteria. Compared with a dedicated injectable API, this product carries no automatic assurance of sterility because the API is not routinely labeled sterile. Compared with a dedicated oral powder, it may require additional elemental impurity, residual solvent, and particulate documentation if the purchaser selects an injectable-use batch. The practical difference is therefore operational and analytical rather than chemical novelty.
Packaging and storage clauses follow the same route logic. Oral-grade APIs are often packed in fiber drums with double polyethylene liners; injectable-bound APIs are more commonly packed in low-endotoxin pharmaceutical containers, sometimes with nitrogen overlay if the molecule is oxidation-sensitive. If the product listing does not specify packaging grade, the buyer should request the packaging specification and extractables profile, particularly for injections. A change between oral and injectable packaging can affect the endotoxin burden and the visible particulate profile, so the route decision must be made at the release step, not at the point of formulation.
Because the provided text does not include a manufacturer model number, the practical model identifier is the full trade-name string plus the route list. Users should record the batch number and packaging code from the label; when requesting quotations, the specification sheet should be identified by its document code and revision date, not only by the commercial name. For multi-route APIs, multiple versions of the same trade name may exist: one intended for oral premix, one for injectable use, and one for high-shear granulation. The supplied listing omits a version code; therefore, the batch certificate becomes the binding model documentation. Buyers should request the manufacturer’s certificate of analysis and compare it against the intended route before release for production.
Materials of construction also shift with the intended route. Stainless-steel contact surfaces of 316L grade are typically specified for solution vessels and transfer lines used for injectable compounding; for dry blending of tablets or premixes, carbon steel may be acceptable if product contact is limited and contamination risk is controlled. Cleaning validation in multi-route plants must address cross-contamination of the same API into feed and injectable equipment, with acceptance limits expressed in parts per million or as maximum allowable carryover. The seven-route label therefore has implications for equipment qualification, not only analytical methods.
For granulation and premix operations, bulk density and segregation behavior determine flow through feed-mill hoppers and auger fillers. A bulk density below 0.35 g/cm³ may cause excessive dust and poor fill weight control in sachet lines; a tapped density above 0.90 g/cm³ may reduce dispersibility in drinking-water solutions. These values are equipment-specific and are not universal acceptance criteria, but they illustrate why the same active substance can fail one route while passing another. Operators should qualify each formulation with a small-scale trial before committing a full API lot.
Humidity control during processing is another route-specific boundary. Tablet and capsule operations benefit from processing rooms maintained below 50% relative humidity; powders for oral solution may require even lower humidity if they contain hygroscopic carriers. Premix operations may tolerate higher ambient moisture if the carrier absorbs it, but mold growth can occur when water activity exceeds 0.6. The product label alone does not define these environmental limits; they must be derived from the formulation stability data and the API moisture sorption isotherm.
During injectable formulation, a 0.22 µm membrane filter is standard for sterilizing-grade filtration, but filter compatibility is not automatic; polyvinylidene difluoride, polyethersulfone, and nylon membranes differ in protein binding and solvent compatibility. If the API is formulated as a supersaturated solution, it may precipitate during filtration or autoclaving at 121 °C for 15 min. Terminal sterilization selection depends on the active molecule’s thermal stability. For oxygen-sensitive actives, nitrogen sparging and headspace flushing are required; for moisture-sensitive actives, dry-heat cycles may be preferable if the compound is stable. These processing decisions are outside the scope of the dry API certificate but directly affect whether the multi-route capability can be realized.
